

Alain Buisson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4445780/publications.pdf>

Version: 2024-02-01

78
papers

5,556
citations

76326

40
h-index

76900

74
g-index

84
all docs

84
docs citations

84
times ranked

6567
citing authors

#	ARTICLE	IF	CITATIONS
1	Astrocyte-neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade. <i>Brain</i> , 2022, 145, 388-405.	7.6	41
2	Tubulin tyrosination regulates synaptic function and is disrupted in Alzheimer's disease. <i>Brain</i> , 2022, 145, 2486-2506.	7.6	17
3	Assembly of The Mitochondrial Complex...I Assembly Complex Suggests a Regulatory Role for Deflavination. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 4689-4697.	13.8	14
4	Pyr1-Mediated Pharmacological Inhibition of LIM Kinase Restores Synaptic Plasticity and Normal Behavior in a Mouse Model of Schizophrenia. <i>Frontiers in Pharmacology</i> , 2021, 12, 627995.	3.5	8
5	VEGF counteracts amyloid- β -induced synaptic dysfunction. <i>Cell Reports</i> , 2021, 35, 109121.	6.4	19
6	Reduction in the neuronal surface of post and presynaptic GABA _B receptors in the hippocampus in a mouse model of Alzheimer's disease. <i>Brain Pathology</i> , 2020, 30, 554-575.	4.1	22
7	Density of GABAB Receptors Is Reduced in Granule Cells of the Hippocampus in a Mouse Model of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2459.	4.1	21
8	Effect of A β Oligomers on Neuronal APP Triggers a Vicious Cycle Leading to the Propagation of Synaptic Plasticity Alterations to Healthy Neurons. <i>Journal of Neuroscience</i> , 2020, 40, 5161-5176.	3.6	13
9	Improved optical slicing by stimulated emission depletion light sheet microscopy. <i>Biomedical Optics Express</i> , 2020, 11, 660.	2.9	7
10	Amyloid Fibers Reveal Themselves With Near-Infrared. <i>Movement Disorders</i> , 2019, 34, 1643-1643.	3.9	0
11	Autophagy Is Required for Memory Formation and Reverses Age-Related Memory Decline. <i>Current Biology</i> , 2019, 29, 435-448.e8.	3.9	150
12	Synaptotoxicity in Alzheimer's Disease Involved a Dysregulation of Actin Cytoskeleton Dynamics through Cofilin 1 Phosphorylation. <i>Journal of Neuroscience</i> , 2018, 38, 10349-10361.	3.6	80
13	A key function for microtubule-associated-protein 6 in activity-dependent stabilisation of actin filaments in dendritic spines. <i>Nature Communications</i> , 2018, 9, 3775.	12.8	30
14	The amyloid- β oligomer A β *56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. <i>Science Signaling</i> , 2017, 10, .	3.6	90
15	GluN2B Subunit Labeling with Fluorescent Probes and High-Resolution Live Imaging. <i>Methods in Molecular Biology</i> , 2017, 1677, 171-183.	0.9	1
16	TRPA1 channels promote astrocytic Ca ²⁺ hyperactivity and synaptic dysfunction mediated by oligomeric forms of amyloid- β peptide. <i>Molecular Neurodegeneration</i> , 2017, 12, 53.	10.8	62
17	Involvement of CRF2 signaling in enterocyte differentiation. <i>World Journal of Gastroenterology</i> , 2017, 23, 5127.	3.3	14
18	Specific alterations of tau phosphorylation and neuronal signaling induced by the amyloid- β oligomer A β *56. <i>Neurobiology of Aging</i> , 2016, 39, S27.	3.1	0

#	ARTICLE	IF	CITATIONS
19	Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata. <i>Glia</i> , 2015, 63, 673-683.	4.9	40
20	Activity-Dependent Tau Protein Translocation to Excitatory Synapse Is Disrupted by Exposure to Amyloid-Beta Oligomers. <i>Journal of Neuroscience</i> , 2014, 34, 6084-6097.	3.6	207
21	Reciprocal disruption of neuronal signaling and $A\beta$ production mediated by extrasynaptic NMDA receptors: a downward spiral. <i>Cell and Tissue Research</i> , 2014, 356, 279-286.	2.9	40
22	Iron overload accelerates neuronal amyloid- β production and cognitive impairment in transgenic mice model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2288-2301.	3.1	106
23	Oxygen glucose deprivation-induced astrocyte dysfunction provokes neuronal death through oxidative stress. <i>Pharmacological Research</i> , 2014, 87, 8-17.	7.1	36
24	NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a transgenic model. <i>Aging Cell</i> , 2013, 12, 11-23.	6.7	64
25	Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B Methyl-D-aspartate Receptor Antagonists. <i>ChemBioChem</i> , 2013, 14, 759-769.	2.6	6
26	Confocal Microscopy Imaging of NR2B-Containing NMDA Receptors Based on Fluorescent Ifenprodil-Like Conjugates. <i>Bioconjugate Chemistry</i> , 2012, 23, 21-26.	3.6	18
27	Interaction Between $CaMKII$ and GluN2B Controls ERK-Dependent Plasticity. <i>Journal of Neuroscience</i> , 2012, 32, 10767-10779.	3.6	60
28	Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. <i>NeuroImage</i> , 2012, 63, 760-770.	4.2	64
29	Selective Impairment of Some Forms of Synaptic Plasticity by Oligomeric Amyloid- β Peptide in the Mouse Hippocampus: Implication of Extrasynaptic NMDA Receptors. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 183-196.	2.6	37
30	O3-04-01: Amyloid-Beta oligomers accumulate in the postsynaptic density fraction and reveal cognitive impairment in transgenic mice model of Alzheimer's disease. , 2011, 7, S505-S505.		0
31	Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[^{18}F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2295-2309.	5.5	29
32	Synapses, NMDA receptor activity and neuronal $A\beta$ production in Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2011, 22, 285-294.	2.9	63
33	Activation of Extrasynaptic, But Not Synaptic, NMDA Receptors Modifies Amyloid Precursor Protein Expression Pattern and Increases Amyloid- β Production. <i>Journal of Neuroscience</i> , 2010, 30, 15927-15942.	3.6	156
34	Copper-catalyzed amination of (bromophenyl)ethanolamine for a concise synthesis of aniline-containing analogues of NMDA NR2B antagonist ifenprodil. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 1111.	2.8	48
35	Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. <i>Molecular and Cellular Neurosciences</i> , 2009, 40, 463-473.	2.2	69
36	p3 peptide, a truncated form of $A\beta$ devoid of synaptotoxic effect, does not assemble into soluble oligomers. <i>FEBS Letters</i> , 2008, 582, 1865-1870.	2.8	40

#	ARTICLE	IF	CITATIONS
37	Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. <i>FASEB Journal</i> , 2008, 22, 4258-4271.	0.5	224
38	Comparison of the pharmacological properties of GK11 and MK801, two NMDA receptor antagonists: towards an explanation for the lack of intrinsic neurotoxicity of GK11. <i>Journal of Neurochemistry</i> , 2007, 103, 1682-1696.	3.9	10
39	P22 REDUCTION OF ISCHEMIC BRAIN DAMAGE BY NITROUS OXIDE AND XENON.. <i>Behavioural Pharmacology</i> , 2006, 17, 547.	1.7	0
40	NMDA Receptor Activation Inhibits β -Secretase and Promotes Neuronal Amyloid- β Production. <i>Journal of Neuroscience</i> , 2005, 25, 9367-9377.	3.6	178
41	Akt-dependent Expression of NAIP-1 Protects Neurons against Amyloid- β Toxicity. <i>Journal of Biological Chemistry</i> , 2005, 280, 24941-24947.	3.4	51
42	Differential role of synaptic and extrasynaptic NMDA receptors in glutamate mediated neuronal injury. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S445-S445.	4.3	0
43	2,7-Bis-(4-Amidinobenzylidene)-Cycloheptan-1-One Dihydrochloride, tPA Stop, Prevents tPA-Enhanced Excitotoxicity Both In Vitro and In Vivo. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 1153-1159.	4.3	20
44	Neurotrophin-3-induced PI-3 kinase/Akt signaling rescues cortical neurons from apoptosis. <i>Experimental Neurology</i> , 2004, 187, 38-46.	4.1	50
45	Is tissue-type plasminogen activator a neuromodulator?. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 594-601.	2.2	65
46	Neuroprotection by Nitrous Oxide and Xenon and Its Relation to Minimum Alveolar Concentration. <i>Anesthesiology</i> , 2004, 101, 260-261.	2.5	14
47	Transforming growth factor-beta and ischemic brain injury. <i>Cellular and Molecular Neurobiology</i> , 2003, 23, 539-550.	3.3	90
48	Reduction of Ischemic Brain Damage by Nitrous Oxide and Xenon. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 1168-1173.	4.3	127
49	Tissue plasminogen activator and NMDA receptor cleavage. <i>Nature Medicine</i> , 2003, 9, 371-372.	30.7	79
50	Reply to "Tissue plasminogen activator and NMDA receptor cleavage". <i>Nature Medicine</i> , 2003, 9, 372-373.	30.7	18
51	Transforming growth factor β -induced expression of type α 1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity. <i>FASEB Journal</i> , 2003, 17, 277-279.	0.5	48
52	Transforming Growth Factor- β 1 Potentiates Amyloid- β Generation in Astrocytes and in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2003, 278, 18408-18418.	3.4	127
53	Le transformant growth factor- β (TGF- β) a-t-il un rôle neuroprotecteur dans l'ischémie cérébrale ?. <i>Société De Biologie Journal</i> , 2003, 197, 145-150.	0.3	3
54	Smad3-Dependent Induction of Plasminogen Activator Inhibitor-1 in Astrocytes Mediates Neuroprotective Activity of Transforming Growth Factor- β 1 against NMDA-Induced Necrosis. <i>Molecular and Cellular Neurosciences</i> , 2002, 21, 634-644.	2.2	77

#	ARTICLE	IF	CITATIONS
55	Transforming Growth Factor- β Modulated Cerebral Gene Expression. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1114-1123.	4.3	24
56	Matching Gene Expression with Hypometabolism after Cerebral Ischemia in the Nonhuman Primate. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1165-1169.	4.3	7
57	Matching Gene Expression With Hypometabolism After Cerebral Ischemia in the Nonhuman Primate. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1165-1169.	4.3	2
58	Neuroprotection Mediated by Glial Cell Line-Derived Neurotrophic Factor: Involvement of a Reduction of NMDA-Induced Calcium Influx by the Mitogen-Activated Protein Kinase Pathway. Journal of Neuroscience, 2001, 21, 3024-3033.	3.6	182
59	Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. NeuroReport, 2001, 12, 289-293.	1.2	103
60	The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nature Medicine, 2001, 7, 59-64.	30.7	678
61	Increased Expression of Transforming Growth Factor- β after Cerebral Ischemia in the Baboon: An Endogenous Marker of Neuronal Stress?. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 820-827.	4.3	37
62	A Soluble Transforming Growth Factor- β (TGF- β) Type I Receptor Mimics TGF- β Responses. Journal of Biological Chemistry, 2001, 276, 46243-46250.	3.4	13
63	Serine Protease Inhibitors: Novel Therapeutic Targets for Stroke?. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 755-764.	4.3	91
64	Ischemia-Induced Interleukin-6 as a Potential Endogenous Neuroprotective Cytokine against NMDA Receptor-Mediated Excitotoxicity in the Brain. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 956-966.	4.3	176
65	Transforming growth factor- β as a regulator of the serpins/tPA axis in cerebral ischemia. FASEB Journal, 1999, 13, 1315-1324.	0.5	96
66	A Transforming Growth Factor- β Antagonist Unmasks the Neuroprotective Role of This Endogenous Cytokine in Excitotoxic and Ischemic Brain Injury. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 1345-1353.	4.3	121
67	Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor- β 1. FASEB Journal, 1998, 12, 1683-1691.	0.5	115
68	Evidence of Type I and Type II Transforming Growth Factor- β Receptors in Central Nervous Tissues: Changes Induced by Focal Cerebral Ischemia. Journal of Neurochemistry, 1998, 70, 2296-2304.	3.9	61
69	Membrane-delimited modulation of NMDA currents by metabotropic glutamate receptor subtypes 1/5 in cultured mouse cortical neurons.. Journal of Physiology, 1997, 499, 721-732.	2.9	76
70	DCG-IV Selectively Attenuates Rapidly Triggered NMDA-induced Neurotoxicity in Cortical Neurons. European Journal of Neuroscience, 1996, 8, 138-143.	2.6	69
71	The inhibitory mGluR agonist, s-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology, 1995, 34, 1081-1087.	4.1	157
72	Nitric Oxide and Cerebral Ischemia. Annals of the New York Academy of Sciences, 1994, 738, 341-347.	3.8	8

#	ARTICLE	IF	CITATIONS
73	Mechanisms Involved in the Neuroprotective Activity of a Nitric Oxide Synthase Inhibitor During Focal Cerebral Ischemia. <i>Journal of Neurochemistry</i> , 1993, 61, 690-696.	3.9	156
74	The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia. <i>British Journal of Pharmacology</i> , 1992, 106, 766-767.	5.4	221
75	Striatal Protection Induced by Lesioning the Substantia Nigra of Rats Subjected to Focal Ischemia. <i>Journal of Neurochemistry</i> , 1992, 59, 1153-1157.	3.9	90
76	Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid. <i>Neuroscience Letters</i> , 1991, 131, 257-259.	2.1	33
77	Lesioning the substantia nigra reduces striatal infarct volume following focal ischemia in rats. <i>Fundamental and Clinical Pharmacology</i> , 1991, 5, 645-647.	1.9	5
78	Combination of horseradish peroxidase and lucifer yellow staining for selective labeling of neurons at the electron microscopic level.. <i>Journal of Histochemistry and Cytochemistry</i> , 1991, 39, 1579-1583.	2.5	3